Aardvark Therapeutics Inc.
Organization details
- Legal name
- Aardvark Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AARD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001774857
- EIN
- 82-1606367
Board of directors
-
Jeffrey Chi · DirectorSince 2025
-
Roy D. Baynes · DirectorSince 2025
-
Susan E. Graf · DirectorSince 2025
-
Tien-Li Lee · Director · Chief Executive OfficerSince 2025
-
Victor Edward Tong Jr. · DirectorSince 2025
-
Zhongwei Zhang · DirectorSince 2026
Chief executives
Director election results
Annual meeting of August 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
76.8%
-
78.7%
Board connections
4 of this board's directors also sit on 5 other boards. 5 are in the same sector.
-
CG Oncology Inc. Same sectorvia Susan E. Graf and Victor Edward Tong Jr.
-
Natera Inc. Same sectorvia Roy D. Baynes
-
Nurix Therapeutics Inc. Same sectorvia Roy D. Baynes
-
Scilex Holding Company Same sectorvia Tien-Li Lee
-
Travere Therapeutics Inc. Same sectorvia Roy D. Baynes
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $144,630
- 2 purchases by 2 insiders
- Sold, last 12 months
- $394,930
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Sun Nelson Officer (See Remarks) | Open-market sale | −62,000 | $5.18 | $321,160 |
| Sep 10, 2026 | Sun Nelson Officer (See Remarks) | Open-market sale | −14,754 | $5.00 | $73,770 |
| Dec 11, 2025 | Sun Nelson Officer (Chief Financial Officer) | Open-market purchase | +3,000 | $14.40 | $43,200 |
| Dec 11, 2025 | Tien-Li Lee Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +7,000 | $14.49 | $101,430 |
| Oct 15, 2025 | Tien-Li Lee Director, Officer (Chief Executive Officer), 10% owner | Option exercise | +1,229 | $4.24 | $5,211 |
| Oct 15, 2025 | Jones Bryan Officer (Chief Operating Officer) | Option exercise | +1,250 | $4.24 | $5,300 |
| Sep 15, 2025 | Tien-Li Lee Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +6,500 | $9.51 | $61,815 |
| Sep 15, 2025 | Tien-Li Lee Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +3,500 | $9.94 | $34,790 |
| Sep 12, 2025 | Tien-Li Lee Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +5,000 | $8.50 | $42,500 |
| Sep 11, 2025 | Tien-Li Lee Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +6,000 | $7.82 | $46,920 |
| Sep 10, 2025 | Tien-Li Lee Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +9,000 | $7.91 | $71,190 |
| Sep 9, 2025 | Sun Nelson Officer (Chief Financial Officer) | Open-market purchase | +6,000 | $8.07 | $48,420 |
| Aug 28, 2025 | Tien-Li Lee Director, Officer (Chief Executive Officer), 10% owner | Option exercise | +17,209 | $4.24 | $72,966 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Derivative conversion | +2,333,887 | — | — |
| Feb 14, 2025 | Jeffrey Chi Director | Derivative conversion | +133,364 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Aardvark Therapeutics Inc.
Who is the CEO of Aardvark Therapeutics Inc.?
Tien-Li Lee has been Aardvark Therapeutics Inc.'s Chief Executive Officer since February 2025.
How many directors are on Aardvark Therapeutics Inc.'s board?
Aardvark Therapeutics Inc.'s board has 6 directors: Jeffrey Chi, Roy D. Baynes, Susan E. Graf, Tien-Li Lee, Victor Edward Tong Jr. and Zhongwei Zhang.
Are Aardvark Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Aardvark Therapeutics Inc. insiders bought $144,630 of shares in 2 purchases and sold $394,930 of shares in 2 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="aardvark-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.